Literature DB >> 30458288

A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis.

Huo Zhang1, Mingxia Zhu2, Xia Shan3, Xin Zhou1, Tongshan Wang1, Jinying Zhang1, Jinsong Tao4, Wenfang Cheng5, Gang Chen6, Jian Li4, Ping Liu7, Qiang Wang8, Wei Zhu9.   

Abstract

Colorectal cancer (CRC) has been one of the most commonly diagnosed cancers in global. The differential expression profiles of microRNAs (miRNAs) in CRC plasma of patients have the potential to serve as a diagnostic biomarker. We conducted a four-stage study to identify the potential plasma miRNAs for CRC detection. In the initial screening phase, Exiqon panel (miRCURY-Ready-to-Use-PCR-Human-panel-I + II-V1.M) including 3 CRC pools and 1 normal controls (NCs) pool were applied to acquire miRNA profiles. In the training stage (30 CRC VS. 30 NCs) and testing stage (79 CRC VS. 76 NCs), quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to conduct candidate miRNA profiles. Then the identified miRNAs were verified in external validation stage (30 CRC VS. 26 NCs). Expression levels of identified miRNAs were assessed in tissue samples (24 pairs) and plasma exosomes (18 CRC VS. 18 NCs). Receiver operating characteristic (ROC) curves were constructed to evaluate the diagnostic accuracy. Seven miRNAs (miR-103a-3p, miR-127-3p, miR-151a-5p, miR-17-5p, miR-181a-5p, miR-18a-5p and miR-18b-5p) were significantly overexpressed in CRC compared with NCs. Area under the ROC curve of the seven-miRNA signature was 0.762, 0.824 and 0.895 for the training, testing and the external validation stages, respectively. Additionally, miR-103a-3p, miR-127-3p, miR-17-5p and miR-18a-5p were discovered significantly up-regulated in CRC tissues; while miR-17-5p, miR-181a-5p, miR-18a-5p and miR-18b-5p were significantly elevated in CRC plasma exosomes. In conclusion, we established a seven-miRNA signature in the peripheral plasma for CRC detection.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Diagnostic biomarker; Plasma microRNA; qRT-PCR

Mesh:

Substances:

Year:  2018        PMID: 30458288     DOI: 10.1016/j.gene.2018.11.055

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  30 in total

1.  Plasma miR-6089 as potential diagnostic biomarker for retinoblastoma.

Authors:  Xiu-Hong Li; An-Jie Shi; Jia Li; Hong-Feng Yuan
Journal:  Int Ophthalmol       Date:  2021-03-27       Impact factor: 2.031

2.  Machine-learning-based Analysis Identifies miRNA Expression Profile for Diagnosis and Prediction of Colorectal Cancer: A Preliminary Study.

Authors:  Dorota Pawelka; Izabela Laczmanska; Pawel Karpinski; Stanislaw Supplitt; Wojciech Witkiewicz; Barłomiej Knychalski; Joanna Pelak; Paulina Zebrowska; Lukasz Laczmanski
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

Review 3.  Scalable Signature-Based Molecular Diagnostics Through On-chip Biomarker Profiling Coupled with Machine Learning.

Authors:  John Molinski; Amogha Tadimety; Alison Burklund; John X J Zhang
Journal:  Ann Biomed Eng       Date:  2020-08-20       Impact factor: 3.934

Review 4.  Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer.

Authors:  Renyi Wu; Lujing Wang; Ran Yin; Rasika Hudlikar; Shanyi Li; Hsiao-Chen D Kuo; Rebecca Peter; Davit Sargsyan; Yue Guo; Xia Liu; A N Kong
Journal:  Mol Carcinog       Date:  2019-12-09       Impact factor: 4.784

5.  Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients.

Authors:  Daniel Sur; Loredana Balacescu; Simona S Cainap; Simona Visan; Laura Pop; Claudia Burz; Andrei Havasi; Rares Buiga; Calin Cainap; Alexandru Irimie; Ovidiu Balacescu
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

6.  MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B.

Authors:  Yimin Chen; Shuyi Chen; Jielun Lu; Danyun Yuan; Lang He; Pengfei Qin; Huo Tan; Lihua Xu
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 7.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

8.  MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer.

Authors:  Shiyu Zhang; Cheng Liu; Xuan Zou; Xiangnan Geng; Xin Zhou; XingChen Fan; Danxia Zhu; Huo Zhang; Wei Zhu
Journal:  PeerJ       Date:  2021-05-19       Impact factor: 2.984

Review 9.  Current Search through Liquid Biopsy of Effective Biomarkers for Early Cancer Diagnosis into the Rich Cargoes of Extracellular Vesicles.

Authors:  Irène Tatischeff
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Inhibiting roles of FOXA2 in liver cancer cell migration and invasion by transcriptionally suppressing microRNA-103a-3p and activating the GREM2/LATS2/YAP axis.

Authors:  Guangzhen Ma; Jirong Chen; Tiantian Wei; Jia Wang; Wenshan Chen
Journal:  Cytotechnology       Date:  2021-05-26       Impact factor: 2.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.